New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
07:13 EDTNNVCNanoViricides signs confidential disclosure agreement with Viroclinics
NanoViricides has signed a “confidential disclosure agreement" with Viroclinics Biosciences, BV, a spinoff of the Department of Viroscience at the Erasmus Medical Centre in Rotterdam, the Netherlands. The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides , such as FluCide, against viruses of mutual interest to both organizations.
News For NNVC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
09:14 EDTNNVCNanoViricides provides quarterly report
NanoViricides filed its quarterly report with the SEC estimating that it now has approximately $36.4M of current assets plus restricted cash as of December 31, 2014. The company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter. The company reported that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate. The company's anti-Ebola nanoviricide drug candidates have been sent for testing at a prestigious BSL4 facility in the .S. The company has the ability to produce sufficient quantities of a successful drug candidate for potential field use. The company estimates that the cash in hand is sufficient to enable initial human clinical trials of injectable FluCide drug candidate, as well as possibly to advance another drug candidate towards initial human clinical trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use